Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2011;38(5):502-7.

First human trial of KW39 slotted-tube stents: for percutaneous coronary intervention

Affiliations
Clinical Trial

First human trial of KW39 slotted-tube stents: for percutaneous coronary intervention

Minoru Tanaka et al. Tex Heart Inst J. 2011.

Abstract

The KW39 stent is a balloon-expandable, stainless-steel, slotted-tube stent, newly designed to adjust to the shape of the coronary arteries. We evaluated the clinical efficacy and safety of KW39 stent-based percutaneous coronary interventions in human native coronary arteries. A total of 105 patients (110 lesions), with a diagnosis of stable angina, acute coronary syndrome, or asymptomatic myocardial ischemia, were included in this prospective study. The primary endpoint was the target-lesion revascularization rate at the conclusion of a 6-month follow-up period. The secondary endpoints were the rates of technical and procedural success and the rate of major adverse cardiac events (defined as cardiac death, myocardial infarction, and target-lesion revascularization) in the course of the 6 months after stent placement. The 6-month target-lesion revascularization rate was 8.6%. The KW39 stent was highly satisfactory in regard to all secondary endpoint comparisons. Binary (>50%) in-stent restenosis was observed in 22 of 110 lesions (20%). The mean diameter stenosis at 6 months after percutaneous coronary intervention was 35.1% ± 14.4%, and the mean late lumen loss was 1.06 ± 0.48 mm. Stepwise multivariate analysis showed probable causal associations between adverse local environments for stent implantation and the subsequent need for target-lesion revascularization. We conclude that KW39 stent implantation was technically feasible and clinically safe in the patient population that we studied. The results of the safety endpoints, including cardiac death and acute myocardial infarction, were acceptable.

Keywords: Coronary interventions, percutaneous; coronary restenosis/prevention & control; equipment design; equipment safety; humans; pliability; prospective studies; prosthesis design; stents; stress, mechanical; treatment outcome.

PubMed Disclaimer

Figures

None
Fig. 1 The KW39 stent is a stainless-steel (SUS316L), flexible, slotted-tube stent with a 0.10-mm strut thickness, a 0.12-mm cellular width, and a 0.06-mm width of the S-shaped link. Digitized images show the KW39 stent A) before and B) after expansion. C) Photograph of the KW39 stent. D) Scanning electron microscopic image of the KW39 stent.
None
Fig. 2 Kaplan-Meier estimates of cumulative incidence of target-lesion revascularization (TLR) in accordance with 105 patients' arterial wall regularity (n = 65) or irregularity (n = 40).

Similar articles

Cited by

References

    1. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007;356(10):998–1008. - PubMed
    1. Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation 2009;119(25):3198–206. - PubMed
    1. Greenhalgh J, Hockenhull J, Rao N, Dundar Y, Dickson RC, Bagust A. Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes. Cochrane Database Syst Rev 2010;(5):CD004587. - PubMed
    1. Babapulle MN, Joseph L, Belisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 2004;364(9434):583–91. - PubMed
    1. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 2006;27(23):2784–814. - PubMed

MeSH terms

Substances